is based on the prevention of aluminium exposure [1] Background. The recommended dose of desferriox-and increased removal of aluminium by dialysis [2, 3] . amine for the treatment of aluminium intoxication is Nevertheless, aluminium transfer during dialysis is 5 mg/kg/week. However, there are no data about the limited because serum aluminium is bound to high efficiency of lower doses. The objective of this study molecular weight proteins, mainly transferrin, and, was to investigate the capacity of very low doses of therefore, it is not dialysable. desferrioxamine in the generation of ultrafiltrable
Introduction
were included in the study. The mean time on haemodialysis (HD) was 9.2±4.6 years (two of them had a previous renal Aluminium is still an important cause of morbidity in transplantation). Three patients were on conventional HD dialysis patients. Treatment of aluminium intoxication and the remaining two patients were treated by paired filtration dialysis (PFD). Desferrioxamine was not used in Table 1 .
Hospital Central de Asturias, c/ Julian Claveria s/n, E-33006 Oviedo, Asturias, Spain.
One week before the beginning of the study, ingestion of administration (post-DFO-pre-DFO). All doses of desferrioxamine (0.5, 2.5 and 5.0 mg/kg) aluminium hydroxide was stopped (three patients). Iron increased the ultrafiltrable aluminium. The increase in supplementation was also withdrawn during the experiment. ultrafiltrable aluminium obtained with 2.5 mg/kg was double, and that with 5.0 mg/kg was almost triple the increase obtained with 0.5 mg/kg (P<0.05, Table 3 ).
Procedure
However, the doses of desferrioxamine needed to obtain such a difference were 5 and 10 times higher,
Desferrioxamine from Ciba-Geigy was administered once per week, at three different doses (0.5, 2.5 and 5.0 mg/kg) respectively. Thus, if we evaluate the efficiency of each for 5 weeks, following the scheme shown in Figure 1 . The dose as the ratio of increase of ultrafiltrable aluminium order of the three different doses was assigned randomly to the dose administered (mg/l of ultrafiltrable alumi-(0.5, 2.5 or 5.0 mg/kg) with a 1 week interval between the nium per mg/kg of desferrioxamine administered), the three different doses.
dose of 0.5 mg/kg was more efficient than 2.5 mg/kg Before administration, desferrioxamine was diluted using and the latter more efficient than 5 mg/kg (all 5% glucose. The smaller dose (0.5 mg/kg), was administered differences P<0.05) ( Table 3, Figure 2 ). in 1 min and the other two doses were infused over 10 min
The increase in the total serum aluminium was at the end of the dialysis session.
higher with 2.5 and 5 mg/kg desferrioxamine; no signiSamples of blood from the arterial line were drawn before ficant differences were found between these two doses and 44 h after the infusion of desferrioxamine for the measurement of total and ultrafiltrable aluminium.
( Table 3 ). Although 0.5 mg/kg is 10 times lower than In vitro ultrafiltration of all the samples was carried out the highest dose (5 mg/kg), the increase in total serum according to the methodology described previously [13] using aluminium obtained using 0.5 mg/kg was less than five the micropartition system AmiconB (MPS-1, Danvers, MA) times lower than the increase obtained with 5 mg/kg. Statistical analysis was performed using the Wilcoxon test in adequately controlling serum phosphorus has forced Fig. 1 . Desferrioxamine temporal scheme followed in the experiment. Each patient received the three different doses of desferrioxamine. The order of each dose was assigned randomly. Samples were taken before the administration of desferrioxamine (post-HD) and at the beginning of the next dialysis session. aluminium ranged between 60 and 85% when desferri-
oxamine was administered at doses ranging between 5 and 100 mg/kg [7] [8] [9] [10] [11] [12] . This led us to believe that even P<0. 05 Our results demonstrate that even very low doses of desferrioxamine (0.5 mg/kg) increase the ultrafiltrable serum aluminium (potentially removable by dialysis). Although the increase of total and ultrafiltrable aluminium was lower with 0.5 mg/kg compared with the other two doses (2.5 and 5.0 mg/kg), the efficacy of the lowest dose in the generation of ultrafiltrable aluminium was higher ( Table 3, Figure 2 ). In other words, a 10-fold increase in desferrioxamine (from 0.5 to 5 mg/kg) resulted only in a 2.8-fold increase in ultrafiltrable aluminium ( Table 3 ). The generation of ultrafiltrable aluminium in response to the administration of desferrioxamine was not linear ( Table 3) .
Total serum aluminium increased by 32.6% with 0.5 mg/kg of desferrioxamine, whereas with 5 mg/kg the increment was 101.7% ( Table 2) . Even though the increase in serum aluminium using 0.5 mg/kg might Fig. 2 . Individual analysis of the efficiency of each dose (increase in be considered low (32.6% vs 101.7%), we have to take ultrafiltrable aluminium/dose of desferrioxamine).
into account that the dose of desferrioxamine used was 10 times lower. In summary, the use of very low doses of desferrioxamine would produce a lower net removal the introduction of aluminium-containing phosphate of aluminium. This approach might be used to treat binders leading to a risk of aluminium overload patients for longer and more safely. [14, 15] .
Our study also demonstrated that the increase in Since the introduction of desferrioxamine for the total serum aluminium correlated (r=0.925) with the treatment and diagnosis of aluminium overload in increase in ultrafiltrable aluminium with a slope close dialysis patients, the recommended dose has steadily to 1 (0.98). This finding indicates that the increases in decreased. In vitro studies carried out by our group on serum aluminium induced by desferrioxamine are due serum from healthy volunteers and HD patients to increases in ultrafiltrable (dialysable) aluminium demonstrated that the efficacy of desferrioxamine dis- ( Figure 3) . Therefore, the increments in total serum placement of aluminium from transferrin decreases aluminium may be used as a predictor of the amount when the desferrioxamine concentration in serum is >10 mM. A desferrioxamine concentration above this of aluminium to be removed with desferrioxamine. It
